New entity in Common Kidney disease: Nephrology

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

New entity in Common Kidney disease: Nephrology

The kidney disease crescentic glomerulonephritis rapidly progresses to acute kidney failure and death within months if it is untreated. Even with treatment, many individuals buildup to end-stage kidney disease and require dialysis and sometimes a kidney transplant. New research in mice has identified a potential new drug target for the treatment of crescentic glomerulonephritis. In the study, mice lacking the mannose receptor protein were found to be protected from crescentic glomerulonephritis. This protection was correlated with decreased kidney damage mediated by cells known as macrophages and mesangial cells. Further, macrophages lacking the mannose receptor actually became antiinflammatory in the kidney after they interacted with mesangial cells. Researchers recommend that targeting the mannose receptor might provide a new approach to treating crescentic glomerulonephritis. Mainly, this path would not have the wide-ranging immunosuppressive effects that many current therapies have.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger